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increase in apoptosis compared to controls, a 71% decrease in the
quantitative number of HSCs isolated from these animals was
observed. This depletion of HSCs in the marrow could provide a
niche for donor HSCs to inhabit. Further histologic studies on
lymphoid organs exposed to radiation through TLI are ongoing.
The durable mixed chimerism observed following TLI/ATG condi-
tioning and HCT will be applied to mice affected with the rodent
form of multiple sclerosis (experimental autoimmune encephalomy-
elitis) and to tolerance induction of solid-organ grafts. Summary:The
combination of TLI/ATGnon-myeloablative conditioning and trans-
plantation of allogeneic HSC leads to a durable mixed chimeric state
between donor and host and will next be applied to the induction of
tolerance to autoantigens and alloantigens.
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TACROLIMUS AS PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DIS-
EASE IN REDUCED INTENSITY CORD BLOOD TRANSPLANTATION FOR
ADULT PATIENTS WITH ADVANCED HEMATOLOGIC DISEASES
Miyakoshi, S., Masuoka, K., Kato, D., Takagi, S., Kawano, T.,
Matumura, T., Matuhshi, Y., Uchida, N., Wake, A., Taniguchi, S.
Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Purpose: To evaluate the feasibility of reduced-intensity unre-
lated cord-blood transplantation (RICBT) in adult patients with
advanced hematological diseases. Experimental Design: Thirty-
four patients (median age, 56 years; range, 24-68 years and median
body weight, 57; range 40-75 kg) with advanced hematological
diseases underwent RICBT at Toranomon Hospital between No-
vember 2002 and May 2005. Preparative regimen comprised ﬂu-
darabine 25 mg/m2 on days7 to3, melphalan 40 mg/m2 on day
2 to 1, and 4 Gy total body irradiation on day 1. G-CSF was
used from day 1 to neutrophil engraftment. Graft-versus-host
disease (GVHD) prophylaxis comprised tacrolimus alone. Results:
The underlying diseases were acute myeloid leukemia (n  12),
myelodysplastic syndrome (n  3), acute lymphoblastic leukemia
(n 3), myeloproliferative disorders (n 4), malignant lymphoma
(n  5), adult T-cell leukemia (n  6), and severe aplastic anemia
(n  1). HLA disparities were 5 match (n  1) and 4 match (n 
33). Median infused total cell dose was 2.4  107 /kg (range,
1.6-4.8  107/kg). Thirty-one patients achieved primary neutro-
phil engraftment after a median of 20 days. Cumulative incidence
of complete donor chimerism at day 60 was 94%. Grade II-IV
acute GVHD occurred in 45% of patients, with median onset 36
days. Main regimen related toxicity was diarrhea as gut toxicity
(grade I; n  19, grade II; n  5). Finally 4 patients (12%),
including 3 patients died before neutrophil engraftment, died
within 100 days of transplant due to TRM (CNS complication; n
2 and sepsis; n  2). Primary disease recurred in 12 patients.
Estimated 2-year overall survival was 70%. Fifteen patients dis-
played PER (median onset, day 9), in which the manifestations
included high-grade fever without infections, eruption, and body
weight gain. The symptoms disappeared spontaneously without
use of corticosteroid treatments and serum concentration of ta-
crolimus at transplantation affected the incidence of PER. Discus-
sion:GVHD prophylaxis in adult CBT is mostly cyclosporine, and
the TRM ranges 27-52%. In contrast, TRM in the present study
with tacrolimus was 12%, which was lower than those in previous
reports. Furthermore the PER in RICBT with tacrolimus was
lower incidence and severity than cyclosporine. This study suggests
the possibility that intensiﬁcation of GVHD prophylaxis may de-
crease TRM after RICBT and improve the prognosis. Conclu-
sion: This study demonstrated the feasibility of RICBT in adults.
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POST-TRANSPLANT MONITORING OF ERYTHROID LINEAGE SPECIFIC
CHIMERISM
Armistead, P.1, Mohseni, M.1, Gerwin, R.1, Iravani, M.2,
Ghavamzadeh, A.2, Ritz, J.1,2, Wu, C.J.1,2 1. Dana-Farber Cancer
Institute, Boston, MA; 2. Hematology-Oncology and Bone Marrow
Transplant Research Center, Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran.
Ongoing efforts to improve the toxicity proﬁle of hematopoietic
stem cell transplantation (HSCT) to treat red blood cell disorders
have generated a need to assess red blood cell engraftment. Here
we describe a method, called RNA pyrosequencing, to rapidly
measure lineage speciﬁc chimerism in peripheral blood and mar-
row. The relative number of cells derived from host versus donor
are assessed through quantitative measurement of lineage-speciﬁc
mRNAs using single nucleotide polymorphisms (SNPs) that dis-
tinguish host versus donor transcripts. To assess erythrocyte lin-
eage engraftment, we used the HapMap and Ensembl databases
and direct high-throughput genotyping to identify 10 common
SNPs within 7 RBC-speciﬁc proteins. Using this panel of SNPs,
we directly genotyped 22 patients who underwent allogeneic
HSCT for malignant (CLL, Hodgkins, NHL) and non-malignant
hematologic diseases (sickle cell, polycythemia vera, Blackfan-Di-
amond anemia, thalassemia) and their HLA-matched donors (19
related, 3 unrelated). A median of 3 and 4 SNPs were different
between matched related and unrelated pairs, respectively, and
could be used for RNA pyrosequencing. RNA pyrosequencing led
to consistent results using multiple SNPs and demonstrated mixed
hematopoietic chimerism following HSCT in 13 of the 22 patients.
Patients with malignant disease exhibited equivalent levels of ery-
throid and leukocyte donor engraftment. In contrast, patients with
non-malignant diseases affecting erythropoiesis showed 2-fold
greater RBC donor engraftment compared to WBC engraftment.
RNA pyrosequencing thus provides a rapid method for assessing
functional erythroid lineage chimerism for diseases in which RBC
engraftment is critically important, without requiring the laborious
process of cell isolation. Furthermore, similar methods can be
applied to generate panels of expressed SNPs to quantify other cell
lineages and thus comprehensively assess the impact of multi-
lineage engraftment following treatment with novel transplant
regimens.
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CORRELATION OF ETHNICITY AND SOCIOECONOMIC STATUS WITH
OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Rodriguez, T.E., Toor, A.A., Parthasarthy, M., Smith, S.E.,
Klein, J.L., Stiff, P.J. Bone Marrow Transplant Program, Department
of Medicine, Loyola University Chicago, Maywood, IL.
Background: Higher risk of mortality among Hispanics after
allogeneic hematopoietic stem cell transplantation (HSCT) for
acute or chronic leukemias has been recently reported by the
CIBMTR (J Clin Oncol 2005;23:7032-7042). The authors could
not determine if socioeconomic factors played a roll in this dispar-
ity. As we have treated a signiﬁcant number of Hispanic patients
over the years, and do collect socioeconomic data, we decided to
analyze data from allografts performed at our center.Methods:To
determine the correlation between Hispanic ethnicity, socioeco-
nomic status, and survival after allogeneic HSCT we identiﬁed 422
allogeneic HSCT patients at our institution from January 1993 to
June 2005. We used Medicaid eligibility as a surrogate for socio-
economic status, as patients are eligible for this program if they are
at or below 200% the federal poverty level. Patient Characteris-
tics: Forty-three (10%) patients were Hispanic, and the rest were
white/Caucasian 82%, African American (5%), Asian (1%), and
others 2%. Indications for HSCT for the non-Hispanic group
were AML/MDS (39%), CML (17%), ALL (10%); lymphomas/
myelomas (23%); others: 10% and the Hispanic group CML
(33%); ALL (24%), AML/MDS (24%), lymphomas/ myelomas
(12%) others (7 %). The median age at transplantation for the
Hispanic patients and the non-Hispanic group were 36 years and
42 years respectively. Gender distribution was similar between the
two groups. Higher percentage of Hispanic patients had Medicaid
as a payer (31%) compared to the rest of the group (13%). Results:
The Kaplan-Meier 5-year overall survival (OS) for Hispanic vs. the
rest of the group was not statistically signiﬁcant [54% vs. 43% (P
.372)]. However, the OS for Medicaid Hispanic vs. non-Medicaid
Hispanic was 23% and 70% respectively. Conclusions: Hispanic
ethnicity does not correlate with lower survival after allogeneic
HSCT. Nevertheless, lower socioeconomic status in addition to
Hispanic ethnicity correlates with worse outcome. This trend ob-
served in a single institution study should be evaluated further
based on larger population.
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